EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ADMA Biologics's enterprise value is $1,527.0 Mil.
ADMA Biologics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $258.2 Mil. Therefore, ADMA Biologics's EV-to-Revenue for today is 5.91.
The historical rank and industry rank for ADMA Biologics's EV-to-Revenue or its related term are showing as below:
ADMA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.13 Med: 7.18 Max: 24.75
Current: 5.91
During the past 13 years, the highest EV-to-Revenue of ADMA Biologics was 24.75. The lowest was 3.13. And the median was 7.18.
ADMA's EV-to-Revenue is ranked better than 55.52% of 1032
companies
in the Biotechnology industry
Industry Median: 7.565
vs ADMA: 5.91
As of today (2024-04-20), ADMA Biologics's stock price is $6.27.
ADMA Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.15. Therefore, ADMA Biologics's PS Ratio for today is 5.44.
ADMA Biologics EV-to-Revenue Historical Data
The historical data trend for ADMA Biologics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ADMA Biologics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
10.06
5.83
4.05
6.03
4.31
ADMA Biologics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
6.03
4.52
4.41
3.79
4.31
Competitive Comparison
For the Biotechnology subindustry, ADMA Biologics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, ADMA Biologics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's EV-to-Revenue falls into.
ADMA Biologics's current Enterprise Value is $1,527.0 Mil.
ADMA Biologics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $258.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics's share price for today is $6.27.
ADMA Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 